New longer-term efficacy and safety data from pivotal Phase III ASCEMBL study for recently US-approved Scemblix® (asciminib) in patients with PH+ CML-CP

Early findings from YTB323 and PHE885 CAR-T cell therapies highlight the progress in developing the next generation T-Charge™ Platform

Final analysis from Phase Ib study evaluating efficacy and safety of sabatolimab (MBG453) in combination with HMAs in patients with very high/high-risk MDS and AML

12-month data from Phase II study of iptacopan (LNP023), the anticipated first oral monotherapy in adult PNH patients, evaluating the factor B inhibitor’s ability to control both intra- and extravascular hemolysis

First analysis of Phase II SOLACE-kids data on Adakveo® (crizanlizumab) in pediatric patients aged 12-17 years old with sickle cell disease
Basel, November 4, 2021 — Novartis will highlight new data on Scemblix® (asciminib), recently approved by the US Food and Drug Administration, as well as its next-generation CAR-T platform and the latest research results for an array of hematology medicines at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition (December 11-14; Atlanta and virtually). More than 100 abstracts, including 24 oral presentations, will be shared at the meeting.

New data will be presented for Kymriah® (tisagenlecleucel), as well as CAR-T pipeline compounds YTB323 and PHE885, along with sabatolimab (MBG453), Scemblix® (asciminib), iptacopan (LNP023), Adakveo® (crizanlizumab), Jakavi®* (ruxolitinib) and Promacta®/Revolade® (eltrombopag).

“Novartis is relentless in its pursuit of breakthrough innovation for patients with blood cancers and life-threatening blood disorders,” said Susanne Schaffert, PhD, President, Novartis Oncology. “The breadth of new data presented at ASH demonstrates the promise of our advanced therapeutic platforms with exciting new approaches in immuno-oncology and CAR-T therapies that aim to transform the lives of patients.”

Data highlights include:

Medicine Abstract Title Abstract Number/
Presentation Details
CAR-T Therapies
YTB323 A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel
T-Charge™ Platform, for the Treatment of Patients (Pts) With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Abstract presentation #740
Oral presentation: Monday, December 13, 3:00 PM – 3:15 PM EST
PHE885 Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 Days Using the
T-ChargeTM Platform Abstract presentation #3864
Poster available:
Monday, December 13, 6:00 PM – 8:00 PM EST
Kymriah
(tisagenlecleucel) Efficacy of Tisagenlecleucel in Adult Patients (Pts) With High-Risk Relapsed/Refractory Follicular Lymphoma (R/R FL): Subgroup Analysis of the Phase II ELARA Study Abstract presentation #131
Oral presentation: Saturday, December 11, 1:00 PM – 1:15 PM EST
Kymriah
(tisagenlecleucel) Real-World Outcomes for Pediatric and
Young Adult Patients With Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated With Tisagenlecleucel: Update From the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry Abstract presentation #428
Oral presentation: Sunday, December 12, 9:45 AM – 10:00 AM EST
Kymriah
(tisagenlecleucel) Real-World Efficacy and Safety Outcomes for Patients With Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin’s Lymphoma (aBNHL) Treated With Commercial Tisagenlecleucel: Update From the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry Abstract presentation #429
Oral presentation: Sunday, December 12, 10:00 AM – 10:15 AM EST
Malignant Hematology
Sabatolimab
(MBG453) Efficacy and Safety of Sabatolimab (MBG453) in Combination With Hypomethylating Agents (HMAs) in Patients (Pts) With Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis From a Phase Ib Study Abstract presentation #244
Oral presentation: Saturday, December 11 2:45 PM - 3:00 PM EST
Scemblix
(asciminib) Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor,
vs Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase After ?2 Prior Tyrosine Kinase Inhibitors: Update After 48 Weeks Abstract presentation #310
Oral presentation: Saturday, December 11
4:45 PM – 5:00 PM EST
Scemblix
(asciminib) Trial in Progress: A Multicenter, Open Label, Randomized Phase III Study of Asciminib
(80 mg Once Daily) vs Investigator-selected TKIs in Newly Diagnosed Adult Patients With Chronic Myeloid Leukemia in Chronic Phase Abstract presentation #1478
Poster available:
Saturday, December 11
5:30 PM – 7:30 PM EST
Scemblix
(asciminib) Trial in Progress: A Multicenter, Open-label, Phase Ib/II Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Philadelphia Chromosome–positive Chronic Myeloid Leukemia in Chronic Phase Treated With ?1 Prior Tyrosine Kinase Inhibitor Abstract presentation #2561
Poster available:
Sunday, December 12
6:00 PM – 8:00 PM EST
Jakavi*
(ruxolitinib) Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT) Abstract presentation # 3909
Poster available:
Monday, December 13, 6:00 PM – 8:00 PM EST
Non-Malignant Hematology
Iptacopan
(LNP023) 12-Month Analysis of a Phase 2 Study of Iptacopan (LNP023) Monotherapy for Paroxysmal Nocturnal Hemoglobinuria Abstract presentation #2173
Poster available:
Sunday, December 12
6:00 PM – 8:00 PM EST
Adakveo
(crizanlizumab) Initial Safety and Efficacy Results From the Phase II, Multicenter, Open-Label SOLACE-Kids Trial of Crizanlizumab in Adolescents With Sickle Cell Disease (SCD) Abstract presentation #12
Oral presentation: Saturday, December 11, 10:45 AM – 11:00 AM EST
Adakveo
(crizanlizumab) Characterization of Two Anti-P-Selectin Monoclonal Antibodies (mAbs): Crizanlizumab Shows Comparable or Stronger Effects Versus Inclacumab Across Cell Adhesion Assays In Vitro Abstract presentation #2032
Poster available:
Sunday, December 12
6:00 PM – 8:00 PM EST
Promacta/Revolade
(eltrombopag) Efficacy and Safety of Eltrombopag Combined With Cyclosporine as First-Line Therapy in Adults With Severe Acquired Aplastic Anemia: Results of the Interventional Phase 2 Single-Arm SOAR Study Abstract presentation #2174
Poster available:
Sunday, December 12
6:00 PM – 8:00 PM EST
Adakveo
(crizanlizumab) Early Evaluation of the Use of Crizanlizumab in Sickle Cell Disease: A National Alliance of Sickle Cell Centers Study Abstract presentation #3113
Poster available:
Monday, December 13
6:00 PM – 8:00 PM EST
Product Information
Approved indications for products vary by country and not all indications are available in every country. The product safety and efficacy profiles have not yet been established outside the approved indications. Because of the uncertainty of clinical trials, there is no guarantee that compounds will become commercially available with additional indications.

For full prescribing information, including approved indications and important safety information about marketed products, please visit https://www.novartisoncology.com/news/product-portfolio.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” etc etc .

Novartis Media Relations
E-mail: ?media.relations@novartis.com